Paper Details

  1. Home
  2. Paper Details

Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO).

Author: BrunnerThomas B, GolcherHenriette, GrabenbauerGerhard G, HohenbergerWerner, MeyerThomas, SauerRolf

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Treating ductal pancreatic cancer with surgery alone hasn't shown good results, so combination therapies are needed. Giving chemotherapy and radiation before surgery (neoadjuvant therapy) is more effective than giving these treatments after surgery because it can make the cancer easier to remove completely and reduce spread to lymph nodes. Neoadjuvant therapy is also better tolerated, allowing more patients to receive this combination treatment. Overall survival rates appear to be higher in studies using neoadjuvant therapy compared to studies using treatment after surgery.
Paper Details　
Original Abstract of the Article :
The disappointing results of surgical therapy alone of ductal pancreatic cancer can only be improved using multimodal approaches. In contrast to adjuvant therapy, neoadjuvant chemoradiation is able to facilitate resectability with free margins and to lower lymphatic spread. Another advantage is bett...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1821337/

データ提供：米国国立医学図書館（NLM）

A Multimodal Approach to Pancreatic Cancer: A Collaborative Effort in the Desert of Disease

The battle against [pancreatic cancer] is a formidable challenge, like navigating a vast and treacherous desert. This multi-center study evaluates the efficacy of [neoadjuvant chemoradiation] followed by resection compared to primary resection alone in treating locally resectable or potentially resectable pancreatic carcinoma, a quest for improved outcomes in the face of a challenging disease.

A Multimodal Approach: Combining Forces in the Fight Against Pancreatic Cancer

The study suggests that [neoadjuvant chemoradiation] followed by resection may offer potential advantages over primary resection alone, including improved resectability and lower lymphatic spread. This multi-faceted approach is like forming a caravan in the desert, combining resources and strengths to overcome the challenges of pancreatic cancer.

Finding a Path Through the Desert: A Multimodal Approach to Pancreatic Cancer

This research highlights the potential benefits of a multimodal approach to treating pancreatic cancer. It's like using a combination of techniques and resources to navigate a challenging desert landscape, enhancing the chances of survival and improving overall outcomes.

Dr.Camel's Conclusion

This study showcases the power of collaboration and innovation in the fight against pancreatic cancer. It's like discovering a hidden oasis in the desert, offering a beacon of hope for those facing this challenging disease.

Date :
  1. Date Completed 2007-04-23
  2. Date Revised 2022-01-29
Further Info :

Pubmed ID

17338829

DOI: Digital Object Identifier

PMC1821337

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.